about
Treatment for anemia in people with AIDSHuman recombinant activated protein C for severe sepsisTreatment for anemia in people with AIDSPharmaceutical marketing and the invention of the medical consumerThe status of clinical trials: cause for concern.Genomic medicine: genetic variation and its impact on the future of health care.Outlook: finding improved medicines: the role of academic-industrial collaboration.Shifting emphasis from pharmacogenomics to theragnostics.Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.Breaking a vicious cycle.Opportunities to significantly reduce expenditure associated with cancer drugs.Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.A population-based study of the use of selective serotonin reuptake inhibitors before and after introduction of generic equivalents.'Big pharma' and psychiatry: 'the devil is in the dyad'.Democracy unleashed--unpacking the tooth fairy in drug industry R&D.Beyond unequal access: Acculturation, race, and resistance to pharmaceuticalization in the United States.Regulation of the pharmaceutical industry: promoting health or protecting wealth?How Many “Me-Too” Drugs are Enough? The Case of Physician Preferences for Specific StatinsMedicalization and Marketing
P2860
Q24235994-3AE9887A-497C-472D-A06C-A9C99A099811Q24242859-153DB5AF-89F0-4C8B-AC4B-02179ECD24DEQ24246542-4F020845-EF4B-4A10-AA51-D5D3015BBEA4Q33238998-C503BDEE-9FC7-4F37-96B9-16B141420DC7Q34008551-37E57D63-0F93-4338-BB75-5F9AB33F5164Q35038039-27ED34E7-7D3C-4466-8BE1-C76E0C641878Q36296129-812C4391-5923-46C2-9504-0F45FC0C596EQ36561637-21D599F9-453E-41B8-B1C2-B2C4CD3D192EQ37133388-B03AD982-FA57-4B6E-B7A9-2B1E6AC77F24Q38125603-175B3A55-EDB1-4842-92C7-FF2019F81819Q38673820-03E4EBF2-9C28-4103-ADF4-EFC48338516FQ42619354-C6936D16-4113-429A-9025-F9C1CFC183B4Q47938375-4344FB46-17EC-4312-9C00-4973F2419162Q48342323-2018F142-6219-43C9-9B09-36577FBDC1C6Q53218852-8BFBF8A4-0F8A-45C6-A673-FC8ED10C48FFQ55090880-A3468F20-3E92-4706-A5D3-A62D92E28441Q55553073-6B9E0D33-914F-4650-B1FA-98C22AB8BB0BQ57266853-2B9B6D8B-791F-4EA3-B37C-A402B8455C4DQ57677123-2D064AEB-2801-424F-A577-D3D28FF3C676
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Excess in the pharmaceutical industry.
@en
type
label
Excess in the pharmaceutical industry.
@en
prefLabel
Excess in the pharmaceutical industry.
@en
P356
P1476
Excess in the pharmaceutical industry.
@en
P2860
P304
P356
10.1503/CMAJ.1041594
P407
P577
2004-12-01T00:00:00Z